3TC and AZT. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


3TC and AZT. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

Treat Rev. 1995 Mar/Apr;(no 17):2. Unique Identifier : AIDSLINE AIDS/95700317


Abstract: The combination of AZT and 3TC has proven to be effective in reducing HIV levels in some people in several clinical trials recently reported on at a scientific conference in Scotland. People taking this combination did not experience any more side effects than if they were taking AZT alone. It was also discovered in test tube studies and in Phase I and Phase II studies that 3TC was very effective against the hepatitis B virus. It has not yet been determined whether this combination helps HIV positive people live longer. Glaxo Pharmaceuticals has made 3TC available through a special program while the drug is awaiting approval from the Food and Drug Administration (FDA). For more information on how to get 3TC and other experimental or approved drugs, call (800) 734-7104.
Keywords: Antiviral Agents/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/ *THERAPEUTIC USE Drug Therapy, Combination Human HIV Infections/*DRUG THERAPY Zalcitabine/ANALOGS & DERIVATIVES/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/*THERAPEUTIC USE Zidovudine/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/*THERAPEUTIC USE NEWSLETTER ARTICLE CLINICAL TRIALKWDantiviralagents/administration&dosage/adverseeffects/KWDtherapeuticusedrugtherapy,combinationhumanhivinfections/KWDdrugtherapyzalcitabine/analogs&derivatives/administration&dosage/adverseeffects/KWDtherapeuticusezidovudine/administration&dosage/adverseeffects/KWDtherapeuticusenewsletterarticleclinicaltrial
951030
M95A0929

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .